Inhibition of neovascularization using VEGF-specific oligonucleo

Details Inhibition of neovascularization using VEGF-specific oligonucleo Inhibition of neovascularization using VEGF-specific oligonucleo

1995-07-12

1998-01-20

Rories, Charles C. P.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

435375, 435377, 536 231, 536 243, 536 2431, 536 2433, 536 245, 536 251, A61K 4800, C12N 510, C07H 2102, C07H 2104

Patent

active

057101361

ABSTRACT:
Disclosed are methods of reducing neovascularization and of treating various disorders associated with neovascularization. These methods include administering to a tissue or subject a synthetic oligonucleotide specific for vascular endothelial growth factor nucleic acid effective in inhibiting the expression of vascular endothelial growth factor.

REFERENCES:
patent: 5332671 (1994-07-01), Farrara et al.
patent: 5585479 (1996-12-01), Hoke et al.
Monia et al. (1993) Journal of Biological Chemistry 268:14514-14522.
Uhlmann et al. (1990) Chemical Reviews 90:543-584.
Detmar et al. (1994) Journal of Experimental Medicine 180:1141-1146.
Detmar et al. (1995) Journal of Investigative Dermatology 105:44-50.
Brown et al. (1995) Journal of Investigative Dermatology 104:744-749.
W. Jamer Antivir. Chem. & Chemoluc. 2(4)191-214, 1991.
B. Tseng et al. Cancer Gene Therapy 1(1) 65-71, 1994.
Michaelson (19480 Trans. Ophthalmol. Soc. U.K. 68:137-180.
Ashton et al. (1954) Br. J. Ophthalmol. 38:397-432.
Am J. Ophthalmol. (1976) 81:383-396.
Knighton et al. (1983) Science 221:1283-1285.
Senger et al. (1986) Cancer Res. 46:5629-5632.
Folkman et al. (1987) Science 235:442-446.
Ophthalmol. (1991) 18:741-840 (Supplement).
Klagsbrun et al. (1991) Ann. Rev. Physiol. 53:217-239.
Tischer et al. (1991) J. Biol. Chem. 266:11947-11954.
Claffey et al. (1992) J. Biol. Chem. 267:16317-16322.
Plate et al. (1992) Nature 359:845-848.
Plouet et al. (1992) Invest. Ophthalmol. Vis. Sci. 34:900.
Schweiki et al. (1992) Nature 359:843-845.
Adamis et al. (1993) Biochem. Biophys. Res. Commun. 193:631-638.
Adamis et al. (1993) Invest. Ophthalmol. Vis. Sci. 34:1440.
Kim et al. (1993) Nature 362:841-844.
Miller et al. (1993) Principles and Practice of Ophthalmology, W.B. Saunders, Philadelphia, pp. 760.
Aiello et al. (1994) New. Eng. J. Med. 331:1480-1487.
Aiello et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:1868.
Anonymous (1994) Prevent Blindness America.
Bressler et al., Principles and Practices of Ophthalmology (eds. Albert and Jakobiac), W.B. Saunders Co., Philadelphia, PA) (1994) vol. 2 pp. 834-852.
Foster in Harrison's Principles of Internal Medicine (Isselbacher et al., ed.) McGraw-Hill, Inc., New York (1994) pp. 1994-1995.
Pierce et al. (1994) Int. Ophth. Clinics 34:121-148.
Simorre-Pintel et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:3393-3400.
Smith et al. (1994) Invest Ophthalmol. Vis. Sci. 35:1442.
Smith et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:101-111.
Focus (Jan. 6, 1995).
Ophthalmology World News (1995) p. 26.
Ophthalmology Times (Jan. 16-22, 1995).
Pierce et al., (1995) Proc. Natl. Acad. Sci. (USA) 92:905-909.
Uchida et al., (1995) Antisense Res. & Dev. 5(1):87 (Abstract OP-10).
Nomura et al., (1995) Antisense Res. & Dev. 5(1):91 (Abstract OP-18).
Stull et al. (1995) Pharmaceutical Research 12:465-483.
Westermann et al. (1989) Biomed. Miochim. Acta. 48:85-93.
Milligan et al. (1993) J. Medicanal Chemistry 36:1923-1937.
Miller et al. (1994) Parasitology Today 10:92-97.
Weiss (1991) Science News 139:108-109.
Wagner (1994) Nature 372:333-335.
Pierce et al. (1995) Investigative Ophthalmology & Visual Science 36:Abstract 3990.
Smith et al. (1995) Investigative Ophthalmology & Visual Science 36: Abstract 3992.
Monacci et al. (1993) American Journal Of Physiology 264:c995-c1002.
Garrido et al. (1993) Growth Factors 8:109-117.
Bennett et al., J. Immunol. 1994, 152:3530.
Marshall, Science, 269, 1995, 1050-1055.
Kim et al., Nature, 362, 1993, 841-844.
Uhlmann et al., Chem. Rev., 90(4), 1990, 544-584.
Stein et al., Science, 261, 1993, 1004-1012.
Wu-Pong, Pharm. Tech., 18, 1994, 102-114.
Lafont et al., Lancet, 346, 1995, 1442-1443.
Rojansakul, Adv. Drug. Del. Rev., 18, 1996, 115-131.

Affiliated with

Also associated with

Rating

Inhibition of neovascularization using VEGF-specific oligonucleo does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of neovascularization using VEGF-specific oligonucleo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of neovascularization using VEGF-specific oligonucleo will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-725425